These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 10711577)

  • 21. Combined chemotherapy and preoperative irradiation for locally advanced noninflammatory breast cancer: updated results in a series of 120 patients.
    Lerouge D; Touboul E; Lefranc JP; Genestie C; Moureau-Zabotto L; Blondon J
    Int J Radiat Oncol Biol Phys; 2004 Jul; 59(4):1062-73. PubMed ID: 15234040
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Neoadjuvant chemotherapy of patients with breast carcinoma].
    Jakesz R; Taucher S; Gnant M; Gebhard B; Kandioler D; Rudas M; Djavanmard M; Steger G
    Zentralbl Chir; 1998; 123 Suppl 5():147-50. PubMed ID: 10063601
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Preoperative chemotherapy for operable breast cancer.
    Mamounas EP; Fisher B
    Cancer Treat Res; 2000; 103():137-55. PubMed ID: 10948445
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neoadjuvant chemotherapy before definitive treatment for stage III carcinoma of the breast.
    Schwartz GF; Cantor RI; Biermann WA
    Arch Surg; 1987 Dec; 122(12):1430-4. PubMed ID: 3689121
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The feasibility of minimally invasive surgery for stage IIA, IIB, and IIIA breast carcinoma patients after tumor downstaging with induction chemotherapy.
    Vlastos G; Mirza NQ; Lenert JT; Hunt KK; Ames FC; Feig BW; Ross MI; Buzdar AU; Singletary SE
    Cancer; 2000 Mar; 88(6):1417-24. PubMed ID: 10717625
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The biology of neoadjuvant chemotherapy for breast cancer.
    Cleator S; Parton M; Dowsett M
    Endocr Relat Cancer; 2002 Sep; 9(3):183-95. PubMed ID: 12237246
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Does primary chemotherapy really increase the rate of breast conserving treatments?].
    Hennequin C; Espié M; Misset JL; Maylin C
    Cancer Radiother; 2004 Feb; 8(1):48-53. PubMed ID: 15093201
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic significance of pathological response of primary tumor and metastatic axillary lymph nodes after neoadjuvant chemotherapy for locally advanced breast carcinoma.
    Machiavelli MR; Romero AO; Pérez JE; Lacava JA; Domínguez ME; Rodríguez R; Barbieri MR; Romero Acuña LA; Romero Acuña JM; Langhi MJ; Amato S; Ortiz EH; Vallejo CT; Leone BA
    Cancer J Sci Am; 1998; 4(2):125-31. PubMed ID: 9554929
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Outcomes of Hispanic women with lymph-node positive, HER2 positive breast cancer treated with neoadjuvant chemotherapy and trastuzumab in Mexico.
    Villarreal-Garza C; Soto-Perez-de-Celis E; Sifuentes E; Ruano S; Baez-Revueltas B; Lara-Medina F; Arce-Salinas C; Alvarado-Miranda A; Chavarri-Guerra Y; Caro-Sanchez C; Castañeda-Soto N; Bargallo-Rocha E; Mohar A
    Breast; 2015 Jun; 24(3):218-23. PubMed ID: 25698148
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Emerging role of taxanes in adjuvant and neoadjuvant therapy for breast cancer: the potential and the questions.
    Goble S; Bear HD
    Surg Clin North Am; 2003 Aug; 83(4):943-71. PubMed ID: 12875604
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Response to neoadjuvant chemotherapy in patients with advanced breast cancer: a local hospital experience.
    Khokher S; Mahmood S; Khan SA
    Asian Pac J Cancer Prev; 2010; 11(2):303-8. PubMed ID: 20843105
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neoadjuvant chemotherapy in breast cancer.
    Charfare H; Limongelli S; Purushotham AD
    Br J Surg; 2005 Jan; 92(1):14-23. PubMed ID: 15635596
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Induction chemotherapy in Barrett cancer: influence on surgical risk and outcome.
    Siewert JR; Lordick F; Ott K; Stein HJ; Weber WA; Becker K; Peschel C; Fink U; Schwaiger M
    Ann Surg; 2007 Oct; 246(4):624-8; discussion 628-31. PubMed ID: 17893499
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Use of [(18)F]-FDG PET to predict response to neoadjuvant trastuzumab and docetaxel in patients with HER2-positive breast cancer, and addition of bevacizumab to neoadjuvant trastuzumab and docetaxel in [(18)F]-FDG PET-predicted non-responders (AVATAXHER): an open-label, randomised phase 2 trial.
    Coudert B; Pierga JY; Mouret-Reynier MA; Kerrou K; Ferrero JM; Petit T; Kerbrat P; Dupré PF; Bachelot T; Gabelle P; Giard S; Coeffic D; Bougnoux P; Prevost JB; Paintaud G; Thibault G; Hernandez J; Coudert M; Arnould L; Berriolo-Riedinger A
    Lancet Oncol; 2014 Dec; 15(13):1493-1502. PubMed ID: 25456368
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Primary systemic therapy for operable breast cancer patients: the need for the new generation of trial design.
    Alvarez RH; Hortobagyi GN
    Breast Cancer Res Treat; 2010 Dec; 124(3):701-5. PubMed ID: 20953832
    [No Abstract]   [Full Text] [Related]  

  • 36. Future prospects of neoadjuvant chemotherapy in treatment of primary breast cancer.
    Wang HC; Lo SS
    Semin Surg Oncol; 1996; 12(1):59-66. PubMed ID: 8821411
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Preoperative chemotherapy for locally advanced breast carcinoma at Charity Hospital, New Orleans, Louisiana.
    Cummiskey RD; Mera R; Levine EA
    Am Surg; 1998 Feb; 64(2):103-6. PubMed ID: 9486878
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pathologic response and long-term follow-up in breast cancer patients treated with neoadjuvant chemotherapy: a comparison between classifications and their practical application.
    Corben AD; Abi-Raad R; Popa I; Teo CH; Macklin EA; Koerner FC; Taghian AG; Brachtel EF
    Arch Pathol Lab Med; 2013 Aug; 137(8):1074-82. PubMed ID: 23899063
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Surgery following neoadjuvant therapy in patients with HER2-positive locally advanced or inflammatory breast cancer participating in the NeOAdjuvant Herceptin (NOAH) study.
    Semiglazov V; Eiermann W; Zambetti M; Manikhas A; Bozhok A; Lluch A; Tjulandin S; Sabadell MD; Caballero A; Valagussa P; Baselga J; Gianni L
    Eur J Surg Oncol; 2011 Oct; 37(10):856-63. PubMed ID: 21843921
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tumour size is the only predictive factor of distant recurrence after pathological complete response to neoadjuvant chemotherapy in patients with large operable or locally advanced breast cancers: a sub-study of EORTC 10994/BIG 1-00 phase III trial.
    Fei F; Messina C; Slaets L; Chakiba C; Cameron D; Bogaerts J; Bonnefoi H
    Eur J Cancer; 2015 Feb; 51(3):301-9. PubMed ID: 25578377
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.